Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sepiapterin (PTC923) in Primary BH4 Deficiency
NCT03519711Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jan 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sepiapterin in primary tetrahydrobiopterin deficiency, sponsored by PTC Therapeutics, Inc.. Started Jan 2019; status: completed.
02
Drugs
sepiapterin
03
Conditions
primary tetrahydrobiopterin deficiency
Beyond the preview
Go deeper on NCT03519711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519711.